TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07756281: First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

Sponsor: ParVation Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07756281 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07756281 Rescue Dossier →